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Abstract: Alterations in cell cycle progression seem to be associated with neuronal death in Alzheimer’s disease 
(AD) and amyotrophic lateral sclerosis (ALS). We previously reported disturbances in the control of cell 
survival/death fate in immortalized lymphocytes from AD patients. These cell cycle dysfunction and impaired 
apoptosis were considered systemic manifestations of AD disease. The purpose of this study was to evaluate 
whether these abnormalities are characteristic of AD, or they may be seen in other neurodegenerative disorders 
such ALS. Our results indicate that alterations in signaling molecules, Akt and ERK1/2, and in the cyclin-
dependent kinase complex inhibitors (CDKis) p21Cip1 and p27Kip1 are detectable in lymphoblasts from AD 
patients, but not in ALS patients, suggesting that these variables may be considered for the development of 
biomarkers of AD. However, lymphocytes from ALS patients do not represent a useful model to study cell cycle-
related events associated with neurodegeneration of motoneurons. 
Keywords: Alzheimer’s disease, amyotrophic lateral sclerosis, lymphocytes, cell proliferation, apoptosis, p21, p27, 
PI3K/Akt, ERK1/2 
 
Introduction 
 
Neuronal death is involved in the onset of 
irreversible manifestations of Alzheimer’s 
disease (AD) and amyotrophic lateral sclerosis 
(ALS). In AD brain, neuronal loss occurs in the 
memory system of the association cortex, 
whereas in ALS the upper and lower motor 
neurons are affected. Although AD and ALS 
differ in important ways, they also have 
common pathogenic features, including 
neuroinflammation, and oxidative and 
mitochondrial dysfunction leading to 
apoptosis. 
 
There is increasing evidence suggesting that 
regulatory proteins of cell cycle progression 
are also involved in the pathogenesis of 
neurodegenerative disorders and in the 
apoptotic death of injured neurons. Cell cycle 
disturbances have been observed in a number 
of neurological diseases including AD [1, 2] 
and ALS [3, 4]. In these studies, it has been 
suggested that cell cycle signaling might affect 
neuronal death pathway. The cell cycle is 
associated with the phase specific expression 
or modification of defined sets of regulatory 
genes that control proliferation, differentiation 
or entry into a quiescent state [5]. However, re-
entry of quiescent, terminally differentiated 
neurons into the cell cycle may result in a 
mitotic catastrophe and cell death [6-9]. 
 
Previous work demonstrated that cell cycle 
regulatory deficit is not only restricted to 
neurons of AD. It has also been observed in 
lymphocytes or fibroblasts of AD [10-13], thus 
providing a useful tool to further study the 
involvement of cell cycle-related events in the 
pathogenesis of AD and for the search of 
treatment strategies. Moreover, lymphocytes 
from ALS subjects have been shown to exhibit 
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traits of the disease [14]; however, as far as 
we know the possible dysfunction of cell 
survival/death mechanisms has not been 
studied in peripheral cells from ALS subjects. 
 
Lymphoblasts from AD patients exhibit an 
enhanced stimulation of proliferation and 
survival compared with that from control 
individuals [13, 15-17]. The enhanced 
proliferative activity of the AD cell lines was 
associated with a high degree of 
phosphorylation of Akt and downregulation of 
the inhibitors of the G1-S checkpoint of the cell 
cycle, p21 and p27, while the increased 
survival of serum-deprived AD cells was 
accompanied by diminished ERK1/2 
activation. To investigate whether these 
abnormalities are characteristic of AD or they 
are common to neurodegenerative disorders, 
we generated lymphoblastoid cell lines from 
ALS patients and compared the cellular 
response to serum to that of AD lymphoblasts. 
 
Our results indicate that alterations in 
signaling molecules, Akt and ERK1/2, and in 
the CDKi p21 and p27 are detectable in 
immortalized lymphocytes of patients with AD, 
but not patients with ALS, suggesting that 
these variables may be considered for the 
development of biomarkers of AD. However, 
lymphocytes from ALS patients do not 
represent a useful model to study cell cycle-
related events associated with 
neurodegeneration of motoneurons. 
 
Materials and Methods 
 
Materials 
 
Polyvinylidene fluoride (PVDF) membranes for 
western blots were purchased from Bio-Rad 
(Richmond, CA). Rabbit polyclonal antibodies 
(pAbs) against human phospho-Akt (Ser473), 
phospho-ERK1/2, total ERK1/2 were obtained 
from Cell Signaling (Beverly, MA), and pAbs 
such as rabbit anti-human p27 (sc-528) and 
p21 (sc-397), and goat anti-human total Akt 
(sc-1618) were from Santa Cruz 
Biotechnologies (Santa Cruz, CA). The 
enhanced chemiluminiscence (ECL) system 
was from Amersham (Uppsala, Sweden). 
Tissue culture media and reagents were 
obtained from Invitrogen (Carlsbad, CA). 
 
Cell Lines 
 
20 patients diagnosed in the Department of 
Neurology of the University Hospital Doce de 
Octubre  (Madrid, Spain) of probable Alzheimer 
according to NINCDS-ADRDA (National 
Institute of Neurological and Communicative 
Diseases and Stroke-Alzheimer’s Disease and 
Related Disorders Association) criteria [18]. Of 
the 20 patients, 7 had mild AD (DSM-III-R, Mini 
Mental State Examination (MMSE) score 
between 18-24), 5 had moderate AD 
(MMSE:10-18), and 8 had severe AD (MMSE: 
<10). 10 patients suffering from ALS 
(diagnosed based on the revised El Escorial 
criteria were used in this study [19]. A group of 
20 healthy individuals was used as control. A 
summary of demographic and clinical 
characteristics of all subjects enrolled in this 
study is reported in Table 1. 
 
 
Table 1  Summary of study population 
 AD ALS HC 
Age 75±2 63±3 71±2 
Age range 59-89 46-79 43-82 
Gender 
Male 
Female  
 
9 
11 
 
5 
5 
 
8 
12 
Total 20 10 20 
HC, healthy control individuals, no sign of neurological 
disease; AD, patients with a diagnosis of probable AD; 
ALS, patients with a diagnosis of amyotrophic lateral 
sclerosis. Values are expressed as mean±SE. 
 
 
All study protocols were approved by the 
Spanish Council of Higher Research 
Institutional Review Board and are in 
accordance with National and European Union 
Guidelines. In all cases, peripheral blood 
samples were taken after written informed 
consent of the patients or their relatives. 
 
Establishment of lymphoblastic cell lines was 
performed in our laboratory as previously 
described [20] by infecting peripheral blood 
lymphocytes with the Epstein Barr virus (EBV) 
[21]. Cells were grown in suspension in T 
flasks in an upright position, in approximately 
10 ml of RPMI-1640 (Invitrogen) medium that 
contained 2 mM L-glutamine, 100 　µg/ml 
streptomycin and, unless otherwise stated, 10 
% (v/v) fetal bovine serum (FBS) and 
maintained in a humidified 5% CO2 incubator 
at 37oC. Fluid was routinely changed every two 
days by removing the medium above the 
settled cells and replacing it with an equal 
volume of fresh medium. 
 
Determination of Cell Proliferation 
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Proliferation was determined by cell counting 
in a Neubauer chamber. EBV immortalized 
lymphocytes from control and AD individuals 
were seeded at an initial cell concentration of 
1x106 cells/ml. Cells were enumerated 
everyday thereafter. Potential toxicity of the 
reagents used was routinely checked by trypan 
blue exclusion under inverted phase-contrast 
microscopy. 
 
Preparation of Cell Extracts 
 
To prepare whole cell extracts, cells were 
harvested and washed in PBS and then lysed 
in ice-cold lysis buffer (20mM Hepes pH 7.9, 
25% glycerol, 0.4M NaCl, 50mM NaF, 1mM 
EDTA, 1mM EGTA, 1mM DTT), containing 1mM 
sodium orthovanadate, 1mM PMSF, 1mM 
sodium pyrophosphate and protease inhibitor 
complete mini mixture (Roche, Mannhein). 
 
Western Blot Analysis 
 
50-100 µg of whole cell extracts were 
fractionated on a SDS polyacrylamide gel, and 
transferred to PVDF membrane (Immobilon-P). 
The amount of protein and the integrity of 
transfer were verified by staining with 
Ponceau-S solution (Sigma). The filters were 
then blocked with non-fat milk and incubated 
at 4ºC overnight, with primary antibodies from 
Santa Cruz at the following dilutions: 1:500 
anti-p27, 1:500 anti-p21, 1:1000 anti-
phospho Akt, 1:1000 anti-Akt, 1:500 anti-
phospho ERK1/2, 1:2000 anti-ERK1/2, and 
1:2000 anti-actin. Signals from the primary 
antibodies were amplified using species-
specific antisera conjugated with horseradish 
peroxidase (Sigma) and detected with a 
chemiluminiscent substrate detection system 
ECL (Amersham). The relative protein levels 
were determined by scanning the bands with a 
GS-800 imaging densitometer provided with 
the Quantity One 4.3.1. software from BioRad. 
 
Statistical Analysis 
 
Unless otherwise stated, all data represents 
mean±SE. Statistical analysis was performed 
on the Data Desk package (version 4.0) for 
Macintosh. Statistical significance was 
estimated by analysis of variance (ANOVA) 
followed by the Scheffe test for multiple 
comparisons. Differences were considered 
significant at a level of p<0.05. 
 
Results 
Proliferation of Immortalized Lymphocytes 
from Control and AD or ALS Patients 
 
Data in Figure 1 confirms and extends our 
previous finding [13, 15, 17, 22] by showing 
that the serum-induced proliferation of 
lymphoblasts from AD patients is enhanced 
compared with that of cells from healthy 
controls. In contrast, no significant differences 
were observed between control and ALS 
lymphoblasts (Figure 1). 
 
 
 
Figure 1  Scatter plot comparing proliferative activity 
between control and AD or ALS lymphoblasts. 
Immortalized lymphoblasts from control, AD, and 
ALS individuals were seeded at an initial density of 
1 x 106/ml and cultured for 3 days in RPMI medium 
containing 10% FBS. Everyday thereafter, samples 
were taken for cell counting. Values shown are from 
day 3 of culture, and are the mean±SE. Statistical 
significance was determined by ANOVA. 
 
 
Since the mean age of ALS patients was lower 
than that of control or AD subjects, we 
investigated whether the proliferative activity 
of control cells was affected by aging. As 
shown in Figure 2A, there were no differences 
in proliferation of cells derived from subjects 
younger or older than 70 years old. Moreover, 
cell proliferation of lymphoblasts from AD 
patients was not affected by the degree of 
disease progression, as cell lines from mild, 
moderate or severe AD patients show similar 
rates of cell growth (Figure 2B). 
 
Cellular Response to Serum Withdrawal in 
Control and AD or ALS Lymphoblasts 
 
Data in Figure 3 summarizes the cellular 
response to serum deprivation of all cell lines 
used in this study, derived from AD and ALS 
patients and control individuals. In agreement 
with previous observations [16], it is shown 
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Figure 2  Aging does not affect the proliferative 
activity of control cells. Neither AD progression 
influences cell proliferation. A. Scatter plot 
comparing the influence of aging on the 
proliferation of lymphoblasts from control 
individuals. Immortalized lymphocytes from control 
individuals were seeded at an initial density of 1 x 
106/ml and cultured for 3 days in RPMI medium 
containing 10% FBS.  B. lymphoblasts from mild, 
moderate or severe AD were cultured as above. 
Values shown are the mean±SE. 
 
 
that AD lymphoblasts were more resistant to 
serum withdrawal-induced cell death than 
control cells. The cellular response of ALS 
lymphoblasts did not differ from that of control 
cells. In control, as well as in ALS cultures, 
more than 30% of cells died after 3-day period 
of serum starvation, whereas less than 10% of 
AD cells died during the same period of time. 
 
Effect of PI3K/Akt and MAPK Activation on the 
Survival of Control and AD Lymphoblasts 
 
We have recently reported that alterations of 
PI3K/Akt and ERK1/2 signaling pathways 
underlined the abnormal cellular response of 
AD lymphoblasts to the presence or the 
absence of trophic support [15, 16]. Enhanced 
proliferation of AD lymphoblasts was 
associated with increased activation of 
 
Figure 3  Scatter plot comparing cell survival 
following serum deprivation between lymphoblasts 
derived from control, AD or ALS patients. 
Immortalized lymphocytes from control, AD, and ALS 
individuals were seeded at an initial density of 1 x 
106/ml and incubated in serum-free RPMI medium 
for 72 hours. Cell viability was determined by Trypan 
blue exclusion under inverted phase-contrast 
microscopy, and expressed as percentage of the 
initial number of cells at day 0. Values shown are 
the mean±SE. Statistical significance was 
determined by ANOVA. 
 
 
PI3K/Akt as monitored by the stimulation of 
phosphorylation of Akt [15]. Data in Figure 4 
shows, in consonance with the lack of 
stimulation of proliferation of ALS 
lymphoblasts, no changes in the cellular 
content of phosphorylated Akt, compared with 
levels of control cells. As expected, AD cells 
show increased phosphorylation of Akt relative 
to the levels of phospho Akt observed in 
control or ALS cells (Figure 4). PI3K/Akt 
signaling appears to regulate the G1-S 
checkpoint of cell cycle by downregulating the 
levels of two CDK inhibitors p27 and p21 [15, 
17]. It was suggested that PI3K/Akt modulates 
the rate of protein degradation by the 
proteasome, after phosphorylation of specific 
residues of these proteins. Therefore, the 
levels of these proteins were determined in 
control, AD or ALS lymphoblasts. Only cells 
from AD patients exhibit significant lower 
content of p21 and p27 (Figure 5). 
 
The ERK1/2 pathway seems to support 
lethality in immortalized lymphoblasts, as the 
specific inhibitor PD98059 prevented the 
serum withdrawal-induced cell death by 
apoptosis [16]. Moreover, it was shown that 
deprivation of trophic support induced a 
sustained increase in the ERK1/2 
phosphorylation of significantly lower intensity 
in AD lymphoblasts [16]. In this work, we have 
compared the activation of this pathway in 
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Figure 4  PI3K/Akt activation in control, AD and ALS lymphoblasts. Control, AD, and ALS lymphoblasts from 4 
different individuals, were incubated in RPMI containing 10% FBS. Whole cell extracts were prepared 24 h 
thereafter, and were immunoblotted with antibodies anti-phospho-Akt (Ser473) and total Akt. The densitometric 
data represent the mean ± SE. *p< 0.05, significantly different from control cells. 
 
 
 
Figure 5  p21 and p27 protein levels in control,  AD and ALS lymphoblasts. Lymphoblasts from control, AD or ALS 
subjects were seeded at an initial density of 1 x 106 x ml-1 and cultured for 24 h in RPMI medium containing 10% 
FBS.  Thereafter aliquots were taken to prepare cell extracts. Western blots of p21 and p27 proteins in 3 different 
cell lines from control, AD, and ALS individuals are shown. Densitometric analysis of these proteins are shown 
below. Results are means ± SE. *p< 0.05 significantly different from control cells. 
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Figure 6  Activity of ERKs in serum deprived control, AD and ALS lymphoblasts. Lymphoblasts from control, AD, 
and ALS lymphoblasts were serum deprived for 72 h. Thereafter aliquots were taken to prepare cell extracts. The 
relative levels of activation of p42/p44 ERKs were assessed by western blot analysis using phospho-specific 
antibodies. The same membranes were then stripped and reprobed with antibodies against total ERKs. 
Representative Western blots in 4 different cell lines from control, AD and ALS patients are shown. The 
immunoreactive bands were quantified by densitometric analysis. Results shown below are the mean ± SE of 8 
different experiments. *p<0.05 significantly different from control cells. 
 
 
control, AD and ALS cells 72 hours after serum 
deprivation. The activity of the ERK1/2 
pathway was assessed by western blotting, 
using phospho-specific antibodies. Figure 6 
shows the state of activation of the ERK1/2 
pathway in control and AD or ALS 
lymphoblasts. As expected, after 72 hours of 
serum deprivation, the phosphorylation status 
of ERK1/2 in AD cells is significantly reduced 
compared with that of control or ALS 
lymphoblasts. Under these experimental 
conditions, ALS cells undergo apoptosis as 
control cells do (Figure 3). Thus, these 
observations suggest that the sustained, but 
reduced signaling through the ERK1/2 
pathway in AD lymphoblasts protects them 
from the serum withdrawal-induced cell death. 
 
Discussion 
 
Recent work has highlighted the important role 
of neuronal vulnerability in the instigation and 
progression of neurodegenerative diseases 
including AD and ALS [23]. Moreover, a 
number of published studies indicated that 
cell cycle status significantly influence neuron 
vulnerability and neurodegenerative pathways 
[8, 24-26].  The ability to control cell cycle has 
been considered a critical factor in preventing 
neurons entering a vulnerable state with high 
risk for instigation of neurodegenerative 
mechanisms [27]. 
 
Reports from our and other laboratories had 
presented evidences indicating that, while the 
predominant clinical expression arises from 
the SNC, AD and ALS have systemic expression 
at the cellular and molecular levels [12, 15, 
28-31]. Although these alterations appear to 
have no clinical consequences outside the 
central nervous system, their parallel 
expression in peripheral cells and in the brain, 
provide a plausible pathophysiological model 
to explain partly the clinical manifestations. Of 
particular relevance to this work is the fact 
that dysfunction of cell cycle is a more general 
phenomenon affecting cells other than 
neurons in AD patients [10, 11, 13, 15, 22]. 
 
In the present study, we addressed the 
question whether easily peripheral cells from 
patients affected with ALS show altered cell 
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survival/death mechanisms comparable to the 
previously reported for lymphoblastoid cells 
lines from AD patients [13-16, 32]. We found 
that AD cells distinctively proliferate at higher 
rates and showed a decreased vulnerability to 
serum deprivation-induced cell death than 
EBV-immortalized lymphocytes from age-
matched control individuals. In addition, we 
demonstrated that the cellular response to 
serum addition or deprivation was not affected 
by the viral transformation [15, 16], indicating 
that lymphoblastoid cell lines are a useful tool 
to study the involvement of cell cycle-related 
events in the neurodegenerative diseases. 
 
Despite the fact that recent literature has 
shown data regarding systemic manifestation 
in ALS [30, 33], we did not observed changes 
in the proliferative capacity of lymphoblasts 
from ALS patients compared with that of cells 
from healthy individuals. In contrast, 
lymphoblasts from AD patients show an 
enhanced proliferative activity after serum 
stimulation, in agreement with previous 
reports from this laboratory [13, 15, 22]. It was 
reported that overactivation of PI3K/Akt 
signaling pathway in AD cells, was likely 
responsible for the enhanced proliferative 
activity by down-regulating cellular levels of the 
CDKis, p21 and p27 [15]. In contrast, no 
significant change in Akt activity was observed 
in ALS lymphoblasts. Accordingly, p21 and p27 
levels were found to decrease only in cells 
from AD patients. This finding is not in 
agreement with earlier reports showing 
deregulation of CDKis associated with 
neurodegeneration in ALS [4, 34, 35]. A 
possible explanation for this divergence may 
be the use of peripheral cells versus 
motoneurons At present, we cannot ascertain 
whether the lack of changes in cell cycle 
regulators in peripheral cells from ALS patients 
reflects the absence of cell cycle related 
events associated with neurodegeneration in 
ALS, or, on the contrary, cell cycle disturbances 
thought to occur in motoneurons [3], do not 
have systemic manifestations. In this regard, it 
is worth to mention a recent report showing no 
evidence for oxidative stress in fibroblast from 
ALS patients [36], despite the fact of impaired 
stress response in affected motoneurons [37]. 
 
Other distinct feature of AD cells is to be less 
vulnerable than control lymphoblasts to cell 
death induced by serum deprivation [16, 32]. 
A sustained, but lower, activation of ERK1/2 in 
AD cells, as compared with the control group 
seems to protect AD lymphoblasts from death. 
We report here that lymphoblasts from ALS 
patients behave as control cells in response to 
serum withdrawal by showing similar 
phosphorylation of ERK1/2 and equal 
susceptibility to the induced cell death. 
 
Collectively, our results show no major 
alterations in the proliferative capacity or 
vulnerability to serum deprivation-induced cell 
death in ALS lymphoblasts compared with cells 
from control individuals. These observations 
suggest that these cells do not represent a 
useful model to study cell cycle-related events 
associated with motoneurons degeneration. 
 
On the other hand, our findings that cell cycle 
progression, cell survival and their molecular 
regulators are distinctly altered in 
lymphoblasts from AD patients add further 
support in favor of considering AD as a 
systemic disease, underlying as possible 
etiopathogenic mechanism altered 
responsiveness to cell activation agents. 
Considering that changes in the abundance of 
CDK inhibitors had also been detected in AD 
brain [38], and that perturbation in the activity 
of PI3K/Akt and ERK1/2 signaling pathways 
had been detected in AD brains [39-41], our 
results highlight the usefulness of peripheral 
cells from AD patients as potential surrogate 
for diagnosis and therapeutic monitoring of 
AD. 
 
The cell cycle disturbances and alteration of 
the apoptotic response found in AD 
lymphoblasts did not correlate with 
progression of the disease. They seem to be 
early manifestations of the disease. This 
observation is in consonance with recent 
evidence in AD patients and in animal models 
[42, 43] indicating that cell cycle dysfunction is 
an early event in AD pathogenesis. Cell cycle 
proteins have been found in brains of 
individuals with mild cognitive impairment 
(MCI) [42], and cell cycle disturbances have 
also been reported in lymphocytes from MCI 
patients [11]. These observations suggest that 
cell cycle-induced death is a central 
mechanistic feature of AD, and therefore 
alterations in cell cycle/apoptosis regulatory 
proteins may serve as markers of AD disease.  
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